Expertise in
1
conditions

Dr. Lisa Roth

Pediatrics
Lymphoma
520 E 70th St # 3, 
New York, NY 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Expertise in
1
conditions
Lymphoma
520 E 70th St # 3, 
New York, NY 

Overview

Lisa Roth is a Pediatrics provider practicing medicine in New York, New York.

Dr. Roth is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Immune Thrombocytopenic Purpura (ITP), and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 8 clinical trials. Dr. Roth is currently accepting new patients.

Specialties

Pediatrics

Licenses

Pediatric Hematology-Oncology in NY

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Horizon Healthcare
  • EPO
  • POS
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 4 Less Insurance Carriers -

Locations

Lymphoma
520 E 70th St # 3, New York, NY 10021
Other Locations
Pediatric Hematology/Oncology
525 E 68th St # 695, New York, NY 10065

Additional Areas of Focus

Dr. Roth has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Enrollment Status: Recruiting
Publish Date: June 18, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Calaspargase, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Inotuzumab, Leucovorin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Thioguanine, Vincristine
Study Phase: Phase 3
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Enrollment Status: Recruiting
Publish Date: May 05, 2026
Intervention Type: Radiation, Drug, Procedure
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin, Etoposide, Ifosfamide, Irinotecan, Topotecan, Vincristine
Study Phase: Phase 2
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Drug, Radiation
Study Drugs: Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin, Doxorubicin, Etoposide, Hydrocortisone Sodium Succinate, Ifosfamide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, Filgrastim, Nivolumab, Pegfilgrastim, Prednisolone, Prednisone, Rituximab, Rituximab+Hyaluronidase Human, Vincristine Sulfate
Study Phase: Phase 3
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Drug, Biological
Study Drugs: Bleomycin, Brentuximab, Cyclophosphamide, Doxorubicin, Etoposide, Methylprednisolone, Prednisone, Vincristine
Study Phase: Phase 3
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Brentuximab, Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Drug, Other
Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine
Study Phase: Phase 3
A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)
A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)
Enrollment Status: Completed
Publish Date: April 30, 2024
Intervention Type: Drug
Study Drugs: Brentuximab Vedotin, Crizotinib, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Methotrexate
Study Phase: Phase 2
View 6 Less Clinical Trials

2 Total Publications

Germinal Center Cytokines Driven Epigenetic Control of Epstein-Barr Virus Latency Gene Expression.
Germinal Center Cytokines Driven Epigenetic Control of Epstein-Barr Virus Latency Gene Expression.
Journal: bioRxiv : the preprint server for biology
Published: January 23, 2024
Similar Doctors
Expertise in
68
conditions
Dr. Nanette Silverberg
Pediatrics
Expertise in
68
conditions
Dr. Nanette Silverberg
Pediatrics
Referral may be required

Office

10 Union Sq E # 3C, 
New York, NY 
 (2.8 miles away)
212-844-8800
Languages Spoken:
English
See accepted insurances

Nanette Silverberg is a Pediatrics provider practicing medicine in New York, New York. Dr. Silverberg is highly rated in 68 conditions, according to our data. Her clinical expertise encompasses Vitiligo, Molluscum Contagiosum, Pityriasis Alba, and Hypomelanotic Disorder.

Expertise in
14
conditions
Dr. Steven Wolf
Pediatrics
Expertise in
14
conditions
Dr. Steven Wolf
Pediatrics
Referral may be required

Young Adult Institute Inc

220 E 42nd St Fl 8, 
New York, NY 
 (1.2 miles away)
212-273-6515
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Steven Wolf is a Pediatrics provider practicing medicine in New York, New York. Dr. Wolf is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Epilepsy, Lennox-Gastaut Syndrome (LGS), Seizures, Thrombectomy, and Deep Brain Stimulation.

Expertise in
24
conditions
Dr. Mitchell Cairo
Pediatrics
Expertise in
24
conditions
Dr. Mitchell Cairo
Pediatrics
Referral may be required

Cardiology Consultants

19 Bradhurst Ave, 
Hawthorne, NY 
 (23.8 miles away)
914-594-3650
Languages Spoken:
English
See accepted insurances

Mitchell Cairo is a Pediatrics provider practicing medicine in Hawthorne, New York. Dr. Cairo is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Burkitt Lymphoma, Primary Mediastinal B-Cell Lymphoma (PMBCL), B-Cell Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Lisa Roth

How do I make an appointment with Dr. Lisa Roth?

You can book an appointment with Dr. Lisa Roth by calling their office at 646-661-2713. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Lisa Roth a top-rated expert for Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Lisa Roth is classified as an Advanced expert for Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Lisa Roth specialize in?

While Dr. Lisa Roth is a Pediatrics, they have specific expertise in Hodgkin Lymphoma, Classical Hodgkin Lymphoma, and Bone Marrow Transplant. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatrics.

Does Dr. Lisa Roth participate in research or clinical trials?

Yes. Dr. Lisa Roth has published 2 articles and abstracts on conditions like Hodgkin Lymphoma. You can view a list of Dr. Lisa Roth's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Lisa Roth accept my insurance?

Dr. Lisa Roth accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 646-661-2713 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Roth's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile